Ecuador Medical Device Registration Timeline Model: Statutory Periods and Practical Estimates

1. Key takeaways

Article 33 of the new regulation sets the ARCSA assessment period for the simplified procedure at 30 statutory periods (días término), counted from the applicant’s submission date, and expressly excludes the time consumed by applicant corrections. Combined with the 5-day completeness correction of Article 35, the 10-statutory-period payment window, and two technical correction rounds of 60 days each, the real bottleneck lies not in the ARCSA review but in the readiness of the certificate holder and the dossier. Any timeline model that treats the 30 periods as the whole duration will understate the project by weeks or months.

2. Legal basis

Terminology note: statutory periods (días término) are the period-calculation unit of Ecuadorian administrative procedure and follow rules different from working days (días hábiles) and calendar days (días calendario). The concrete conversion should follow the Ecuadorian administrative procedure rules and ARCSA publications as applicable at the time. Schedules built purely in calendar days are a recurring source of missed correction windows.

3. Expert insights

Insight 1: the two sentences of Article 33 separate official processing time from actual project duration. The first sentence grants an assessment period of 30 statutory periods; the second states that the time referred to in the article does not include the time consumed by the applicant in correcting the objections raised by ARCSA. The 30 statutory periods are therefore only the net working time on the ARCSA side. Every correction round suspends the clock, and the suspension can last far longer than the review itself if responses are slow.

Insight 2: only the full chain of milestones constitutes a complete schedule (simplified procedure).

1. Submission of the application (homologation form, until the VUE update);
2. ARCSA verification of risk class and dossier completeness;
3. If corrections are required, correction within 5 days (only once, with final cancellation if missed);
4. Review passed, the system notifies the amount due, payment within 10 statutory periods;
5. Payment verified and invoice issued;
6. ARCSA technical assessment (30 statutory periods);
7. If no observations, the system automatically generates the favorable technical analysis report and issues the certificate;
8. If observations exist, a single consolidated correction report, first round 60 days; if still insufficient, a second and final round of 60 days;
9. Completion of the full general registration dossier within 30 statutory periods after approval (immediate cancellation if missed).

Insight 3: the assessment period of the general procedure floats in the statutory text, an uncertainty that must be faced directly. Article 26(8) states in its original wording that ARCSA will conduct the technical assessment of the product and that the assessment time depends on the risk class, the device type and the complexity of the procedure. The general procedure therefore cannot yield a determinate duration from the regulation itself; industry figures of 2 to 6 months are practical estimates. They should be presented to management as ranges with explicit assumptions, never as commitments.

Insight 4: payment after the review is an underrated cash-flow advantage. Both procedures are identical in this respect: only after the review is passed does the system notify the amount, and the applicant then has 10 statutory periods to pay. Nothing is paid at submission, so the sunk cost of a failed project is lower than in pay-first systems, although Article 18 creates an exception: fees already paid are not refunded where the application is withdrawn after failed corrections.

Insight 5: the real bottleneck is the three cross-border collaboration windows. The 5-day completeness correction, the two 60-day technical correction rounds, and the 30-day post-approval dossier completion all require fast collaboration between the Chinese manufacturer and the Ecuadorian certificate holder. Of these, the 5-day window is the shortest and the easiest to lose control of, because it allows almost no time for international document circulation, translation or re-signing once an observation is notified.

4. Practical recommendations

1. Rebuild the timeline model as a two-stage structure of ARCSA net processing time plus collaboration windows; do not estimate on the 30 statutory periods alone.
2. Establish the 5-day correction authorization and response mechanism with the certificate holder in advance, including pre-signed document templates and local filing authority.
3. Rehearse the payment workflow: confirm that the holder can complete payment and obtain the receipt within the 10 statutory periods.
4. Complete the full general registration dossier before the certificate is granted, ensuring it can be submitted in one pass within the 30-statutory-period completion window.
5. For the general procedure, estimate duration from risk class, device type and complexity, and reserve time for correction rounds.

5. Verification checklist

• □ Built the two-stage timeline model of ARCSA net processing time plus collaboration windows
• □ Established the authorization and response mechanism for the 5-day completeness correction
• □ Rehearsed the payment workflow (10 statutory periods window)
• □ Completed the full general registration dossier before the certificate is granted (30 statutory periods completion window)
• □ Estimated the general procedure duration on the three factors with correction rounds reserved
• □ Confirmed the current calculation rules for statutory periods (días término)

Regulatory information verified as of October 29, 2026

Core service areas

1. Global market access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, plus premarket registration pathway planning and filing execution across Latin America, Southeast Asia, the Middle East and other markets.
2. Authorized representative services: EU authorized representative (EC REP), UK responsible person (UK RP), Swiss authorized representative (CH REP), Australia sponsor and US Agent, together with neutral certificate-holder structure design.
3. Quality system compliance: ISO 13485 implementation and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) authoring and remediation.
4. Clinical and evaluation: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why GRZAN

• Local regulatory teams: filings in each target market are executed by locally licensed regulatory professionals and prepared directly in the official language of the market, without secondary translation.
• Neutral holding structure: certificate-holding arrangements that are not tied to any distribution channel, keeping registrations independent of channel partners.
• Regional leverage: a single technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance cost.
• Full lifecycle support: end-to-end service from classification, pathway design and dossier preparation through certificate holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides medical device registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, certificate-holding structure design, official fee and timeline estimation